To avoid overlaps, the industry is calling for aligning MDR/IVDR with the EU's digital frameworks, pharmaceutical regulations, and clinical trial regulations.

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

Beijing's healthcare industry surpassed 1.06 trillion yuan ($146.2 billion) in scale in 2024, marking an 8.7% year-on-year increase and making it the first city in China to reach this milestone, ...

Amid Trump’s dismantling of DEI, Roche wiped diversity targets from the website of its US subsidiary, Genentech, in mid-February. Basel-based competitor Novartis also said this week it was getting rid ...

DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time ...

Scientists recently unveiled a first-of-its-kind authentication protocol for wireless, battery-free, ultraminiaturized implants that ensures these devices remain protected while still allowing ...

Holding Bitcoin could help biotech firms survive the long period of time it takes to bring products to market, says Atai Life ...

Investing in TSX healthcare stocks such as Kneat.com can help Canadians generate outsized gains in 2025 and beyond. The post ...

Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the coun ...

The proposed merger would create a new ophthalmic company that combines two FDA-approved technologies: Betaliq's EyeSol ® water-free drug delivery technology for use in glaucoma, and Eyenovia's ...

Ravi Udaya Bhaskar said India needs to convey to the US ‘very clearly that the President cannot weaponise tariffs to bully ...